Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

Why Are VRNA Shares Falling Today?

This afternoon we watched Verona Pharma drop -4.2% to a price of $90.59 per share. The Mid-Cap Pharmaceutical company is now trading -23.93% below its average target price of $119.09. Analysts have set target prices ranging from $90.0 to $170.0 per share for Verona Pharma, and have given the stock an average rating of buy.

The stock has an above average percentage of its shares sold short at 10.3%, and a short ratio of 6.19. Since 10.4% of the company's shares are owned by insiders, we can infer that there is a degree of alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 91.0% of Verona Pharma's shares being owned by this investor type.

Institutions Invested in Verona Pharma

Date Reported Holder Percentage Shares Value
2025-03-31 Perceptive Advisors Llc 8% 6,563,340 $594,605,795
2025-03-31 Janus Henderson Group PLC 6% 5,516,889 $499,802,565
2025-03-31 Darwin Global Management, Ltd. 5% 3,923,204 $355,422,671
2025-03-31 Frazier Life Sciences Management, L.P. 4% 3,457,850 $313,263,924
2025-03-31 Eventide Asset Management LLC 3% 2,893,437 $262,130,928
2025-03-31 RTW Investments LP 3% 2,848,800 $258,087,039
2025-03-31 NEA Management Company, LLC 3% 2,688,565 $243,570,549
2025-03-31 Summit Partners Public Asset Management LLC 3% 2,323,115 $210,462,606
2025-03-31 Wellington Management Group, LLP 2% 2,131,502 $193,103,426
2025-03-31 Price (T.Rowe) Associates Inc 2% 1,866,280 $169,075,638

Besides an analyst consensus of strong upside potential, other market factors point to there being positive market sentiment on Verona Pharma.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS